The FDA draft guidance implicitly calls for at least three switches—the minimum number to generate two distinct exposures to both the branded drug and the FoB (#msg-127963701).
MNTA’s phase-3 trial for M934 (Humira FoB) anticipated and satisfies the above requirement, as far as I know (#msg-127945401).
Market Data 
Markets 
AI
